Ocuphire Pharma/OCUP

$2.60

-1.52%
-
1D1W1MYTD1YMAX

About Ocuphire Pharma

Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its pipeline includes two small molecule product candidates targeting several of such indications. Nyxol Eye Drops (Nyxol) is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically induced mydriasis (RM), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (DLD) (halos, glares and starbursts). Its product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases. The Company has also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.

Ticker

OCUP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

George Magrath

Employees

9

Headquarters

Farmington hills, United States

Ocuphire Pharma Metrics

BasicAdvanced
$60.87M
Market cap
2.14
P/E ratio
$1.18
EPS
0.36
Beta
-
Dividend rate

What the Analysts think about Ocuphire Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
669.23% upside
High $24.00
Low $16.00
$2.60
Current price
$20.00
Average price target

Ocuphire Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
46.21% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$11.9M
230.56%
Net income
$5.5M
-212.24%
Profit margin
46.21%
-133.95%

Ocuphire Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 212.61%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$1.58
-$0.28
-$0.24
$0.25
-
Expected
$0.97
-$0.15
-$0.23
-$0.22
-$0.05
Surprise
63.31%
81.82%
6.19%
-212.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ocuphire Pharma stock

Buy or sell Ocuphire Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing